Rhythm Pharma Up 2.6% After EU Approval

Rhythm Pharmaceuticals shares rose 2.6% to $83.45 after European Commission approved its obesity drug Imcivree.
The approval covers treatment of acquired hypothalamic obesity in adults and children aged four and older, a rare disorder.
Imcivree, already US‑approved in March, will be launched commercially across Europe in 2027 via country‑by‑country access applications.
Despite the gain, Rhythm’s stock is down 22.3% year‑to‑date.